Gedatolisib - Pfizer

Drug Profile

Gedatolisib - Pfizer

Alternative Names: PF-05212384; PF-5212384; PKI-587

Latest Information Update: 28 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wyeth
  • Developer Curie Institute; Eastchester Center for Cancer Care; Indiana University; Netherlands Cancer Institute; Pfizer; University of Florida
  • Class Antineoplastics; Morpholines; Piperidines; Small molecules; Triazines; Urea compounds
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; MTOR protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Acute myeloid leukaemia
  • Phase II Colorectal cancer; Non-small cell lung cancer
  • Phase I Breast cancer; Solid tumours
  • Discontinued Endometrial cancer

Most Recent Events

  • 01 Jun 2018 Efficacy and adverse events data from a phase I trial in Breast cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 12 Mar 2018 Pfizer re-initiates patient enrolment in a phase I/II trial in Non-small cell lung cancer (Combination therapy, Inoperable/Unresectable, Metastatic disease, Late-stage disease) in USA (IV) (NCT02920450)
  • 17 Jan 2018 Abramson Cancer Center of the University of Pennsylvania and Translational Breast Cancer Research Consortium plans a phase Ib/II GLACIER trial (Combination therapy, Second-line therapy or greater) for Breast Cancer in USA (IV) (NCT03400254)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top